CoreAge Rx 4Play

What preparation is being proposed?

CoreAge Rx describes 4Play as a compounded combination containing apomorphine, sildenafil, tadalafil and vardenafil. The product page lists 2 mg, 40 mg, 4 mg and 7.5 mg respectively per 2 mL bottle. Those figures describe the provider's formulation, not instructions for a reader to calculate a dose. [CoreAge product page]

The public descriptions use both oral-suspension and sublingual-solution language. Ask the prescribing clinician and pharmacist which preparation will actually be supplied and what its label instructs. The name 4Play does not settle route, frequency or personal suitability. [CoreAge offer]

What does the advertised package include?

The offer presents five bottles for $114, with assessment and shipping included and charging only if a prescription is approved. It describes a total of 10 mL as a one-month pack and an optional automatic-refill arrangement after the first order. A marketed supply period is not a personal use schedule.

Confirm the next payment and the refill choice before enrolling. Ask how a question about the response reaches the clinical team, and how a change in prescription would affect an upcoming shipment. We have not tested ordering, dispensing or cancellation as patients.

What does the featured position mean?

CoreAge Rx receives sponsored first placement here; the position does not establish better clinical outcomes. FDA does not approve compounded drugs, and evidence for a single ingredient cannot validate this particular combination. The Viagra label does not recommend combining it with other PDE5 inhibitors or ED treatments. Discuss the rationale, alternatives and risks with the prescriber. [FDA] [Label]

We do not treat advertised speed or enhanced connection as independently demonstrated results. Read our distinction between desire and erections, then use the care guide to keep the medical decision separate from the commercial placement.